Zobrazeno 1 - 10
of 32
pro vyhledávání: '"David Apelian"'
Autor:
Thomas H King, Charles B Kemmler, Zhimin Guo, Derrick Mann, Yingnian Lu, Claire Coeshott, Adam J Gehring, Antonio Bertoletti, Zi Z Ho, William Delaney, Anuj Gaggar, G Mani Subramanian, John G McHutchison, Shikha Shrivastava, Yu-Jin L Lee, Shyamasundaran Kottilil, Donald Bellgrau, Timothy Rodell, David Apelian
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101904 (2014)
Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antigens. A therapeutic vaccine capable of restoring these immune responses could potentially improve HBsAg seroconversion rates in the setting of direct ac
Externí odkaz:
https://doaj.org/article/7e27258ef8564bc4a5d1fac67125fcb8
Autor:
James W. Hodge, David Apelian, Thomas H. King, Zhimin Guo, Andy Protter, Connie J. Rogers, Benedetto Farsaci, Andressa Ardiani
Purpose: Enzalutamide, a second-generation androgen antagonist, was approved by the U.S. Food and Drug Administration (FDA) for castration-resistant prostate cancer (CRPC) treatment. Immunotherapy has been shown to be a promising strategy for prostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38682d041e6c8d8a249b101e6c2e593e
https://doi.org/10.1158/1078-0432.c.6522542.v1
https://doi.org/10.1158/1078-0432.c.6522542.v1
Autor:
James W. Hodge, David Apelian, Thomas H. King, Zhimin Guo, Andy Protter, Connie J. Rogers, Benedetto Farsaci, Andressa Ardiani
PDF file - 2461K, Supplemental Table 1: Cellular immune responses to multiple tumor antigens after combination therapy with MDV3100 and Twist-vaccine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1475b2ad5d3d8f189e99a4130a0799f3
https://doi.org/10.1158/1078-0432.22452659
https://doi.org/10.1158/1078-0432.22452659
Autor:
Sawa Ito, Christine Voigt, Tim Mayall, Mark J Shlomchik, Jennifer D Roy, Egidio Brocca Cofano, Stephanie Stras, David Apelian, Robert Keefe, Warren D Shlomchik
Publikováno v:
Blood. 140:7482-7483
Autor:
Aysun Çalişkan, Esra Yurdcu, Cihan Yurdaydin, Ingrid Choong, David Apelian, Çağdaş Kalkan, Ersin Karatayli, Fatih Karakaya, Soner Onem, Christopher Koh, Senem Ceren Karatayli, Ramazan Idilman, Mithat Bozdayi, Jeffrey S. Glenn, Onur Keskin, Theo Heller
Publikováno v:
Hepatology (Baltimore, Md.)REFERENCES. 75(6)
BACKGROUND & AIMS Proof-of-concept studies demonstrated lonafarnib (LNF), a first-in-class, oral prenylation inhibitor, efficacy in HDV-infected patients. The LOnafarnib With Ritonavir for HDV-2 (LOWR-2) study's aim was to identify optimal combinatio
Autor:
Timothy C. Rodell, Claire Coeshott, Kristi McIntyre, Joanna Roder, Heinrich Roder, David Apelian, Frank E. Harrell, Allen Lee Cohn, Tanios Bekaii-Saab, William E. Fisher, Alexander S. Rosemurgy, Donald A. Richards, Peter Muscarella, Alicia Mattson, Sharona Ross, Patrick J. Flynn
Publikováno v:
Journal of Pancreatic Cancer
Journal of Pancreatic Cancer, Vol, Iss, Pp-(2021)
Journal of Pancreatic Cancer, Vol, Iss, Pp-(2021)
Purpose: GI-4000, a series of recombinant yeast expressing four different mutated RAS proteins, was evaluated in subjects with resected ras-mutated pancreas cancer. Methods: Subjects (n?=?176) received GI-4000 or placebo plus gemcitabine. Subjects' t
Autor:
Claire Coeshott, Allen Lee Cohn, Michael A. Morse, David Apelian, John Ferraro, Timothy C. Rodell, Bert H. O'Neil, Donald Bellgrau, Samuel Whiting
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
We are developing whole, heat-killed, recombinant Saccharomyces cerevisiae yeast, engineered to encode target proteins, which stimulate immune responses against malignant cells expressing those targets. This phase 1 trial, enrolling patients with adv
Autor:
Gwendoline Poizat, Marie-Claude Homery, David B. Smith, John Fry, Laure Viguerie, Christopher Westland, Alain Patat, Caroline Denot, Qingling Zhang, Jennifer Vuong, Matthew W. McClure, Sushmita Mukherjee Chanda, James Hui, David Apelian, Thomas N. Kakuda
Publikováno v:
Pharmacology Research & Perspectives
This Phase I, open‐label, two‐group, fixed‐sequence study evaluated the pharmacokinetics and safety of AL‐335, odalasvir, and simeprevir in healthy subjects. Group 1 (n = 16) received AL‐335 800 mg once daily (QD) (days 1‐3, 11‐13, and
Autor:
Claire Coeshott, Sandra P. D'Angelo, Alicia Mattson, Jamie E. Chaft, Valerie W. Rusch, Mark G. Kris, Payal R. Patel, Lee M. Krug, Anya Litvak, Maria E. Arcila, David Apelian, Christopher G. Azzoli, Bernard J. Park
Publikováno v:
Clinical Lung Cancer. 15:405-410
Introduction Patients with early-stage lung cancer have a high risk of recurrence despite multimodality therapy. KRAS-mutant lung adenocarcinomas are the largest genetically defined subgroup, representing 25% of patients. GI-4000 is a heat-killed rec
Autor:
David Apelian, John G. McHutchison, Gong Shen, Brian R. Armstrong, Claire Coeshott, Timothy C. Rodell, G. Mani Subramanian, Anuj Gaggar
Publikováno v:
Vaccine. 32:4925-4931
Background GS-4774 is a recombinant, heat-killed, yeast-based immunotherapy engineered to express hepatitis B virus (HBV)-specific antigens. GS-4774 is being developed as a therapeutic vaccine for chronic HBV infection. The aim of this study was to a